This retrospective matched cohort study used the TriNetX US Collaborative Network to compare cardiovascular disease (CVD) risk in adult CSU patients treated with omalizumab (OMA), second-generation antihistamines (sgAH), or oral corticosteroids (oCS), across three pairwise 1:1 propensity-score-matched analyses over up to 3 years.
OMA was consistently associated with the lowest CVD risk: vs. oCS, absolute risk was 3.55% vs. 8.06% (primary analysis), with adjusted hazard ratios of 0.51–0.54 (all p<0.001); sgAH showed modestly lower CVD risk than oCS; the hierarchy OMA < sgAH < oCS was directionally consistent across all predefined time windows and secondary outcomes (MACE, VTE).
Treatment allocation was non-random and may capture disease severity rather than drug effects; omalizumab patients may have had more stable disease, more intensive surveillance, and higher socioeconomic status; disease control was not measured, so whether lower CVD risk reflects drug-specific effects, better CSU control, or residual confounding cannot be determined.
Clinicians managing CSU should be aware that CVD risk varies by treatment choice, with omalizumab associated with the lowest observed risk — but these findings should prompt CVD risk assessment in CSU management rather than be interpreted as proof that omalizumab is cardioprotective.